Stocks in Action USA: KalVista, Tesla, Rocket Lab
Reading Time: 4 minutes
KalVista (KALV) stock takes off: FDA approval for Ekterly causes price surge! The U.S. biopharma specialist KalVista is making waves in the markets at the start of the week: The U.S. Food and Drug Administration (FDA) has granted market approval for the drug Ekterly for the acute treatment of hereditary angioedema (HAE) in patients aged 12 and older. What's special : Ekterly is the first orally administered on-demand treatment for the rare genetically caused condition that triggers sudden life-threatening swelling in the body. Previous therapies...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
